ISIS 113715
Latest Information Update: 05 Apr 2011
At a glance
- Originator Isis Pharmaceuticals
- Class Antisense oligoribonucleotides
- Mechanism of Action Protein tyrosine phosphatase non receptor type 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 01 Mar 2011 Discontinued - Phase-II for Type-2 diabetes mellitus in Poland (SC)
- 01 Mar 2011 Discontinued - Phase-II for Type-2 diabetes mellitus in Russia (SC)
- 29 Jun 2010 Efficacy data from a phase II trial in Type-2 diabetes mellitus (NCT00455598) presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA-2010)